These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 35351488)

  • 1. Rapid treatments for depression: Endocannabinoid system as a therapeutic target.
    Sharafi A; Pakkhesal S; Fakhari A; Khajehnasiri N; Ahmadalipour A
    Neurosci Biobehav Rev; 2022 Jun; 137():104635. PubMed ID: 35351488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
    Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
    J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid anti-depressant-like effects of ketamine and other candidates: Molecular and cellular mechanisms.
    Peng FZ; Fan J; Ge TT; Liu QQ; Li BJ
    Cell Prolif; 2020 May; 53(5):e12804. PubMed ID: 32266752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What is the mechanism of Ketamine's rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities.
    Strasburger SE; Bhimani PM; Kaabe JH; Krysiak JT; Nanchanatt DL; Nguyen TN; Pough KA; Prince TA; Ramsey NS; Savsani KH; Scandlen L; Cavaretta MJ; Raffa RB
    J Clin Pharm Ther; 2017 Apr; 42(2):147-154. PubMed ID: 28111761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Putative role of endocannabinoid signaling in the etiology of depression and actions of antidepressants.
    Gorzalka BB; Hill MN
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1575-85. PubMed ID: 21111017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A review of the antidepressant properties of ketamine].
    Desfossés CY; Blier P
    Med Sci (Paris); 2021 Jan; 37(1):27-34. PubMed ID: 33492215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and Cellular Mechanisms of Rapid-Acting Antidepressants Ketamine and Scopolamine.
    Wohleb ES; Gerhard D; Thomas A; Duman RS
    Curr Neuropharmacol; 2017; 15(1):11-20. PubMed ID: 26955968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How depression and antidepressant drugs affect endocannabinoid system?-review of clinical and preclinical studies.
    Dragon J; Obuchowicz E
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Jul; 397(7):4511-4536. PubMed ID: 38280009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective.
    Hashimoto K
    Psychiatry Clin Neurosci; 2019 Oct; 73(10):613-627. PubMed ID: 31215725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of NMDA receptors in the treatment of major depression.
    Dang YH; Ma XC; Zhang JC; Ren Q; Wu J; Gao CG; Hashimoto K
    Curr Pharm Des; 2014; 20(32):5151-9. PubMed ID: 24410564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine.
    Monteggia LM; Gideons E; Kavalali ET
    Biol Psychiatry; 2013 Jun; 73(12):1199-203. PubMed ID: 23062356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment Resistant Depression with Loss of Antidepressant Response: Rapid-Acting Antidepressant Action of Dextromethorphan, A Possible Treatment Bridging Molecule.
    Lauterbach EC
    Psychopharmacol Bull; 2016 Aug; 46(2):53-58. PubMed ID: 27738380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sex Differences in the Behavioral, Molecular, and Structural Effects of Ketamine Treatment in Depression.
    Ponton E; Turecki G; Nagy C
    Int J Neuropsychopharmacol; 2022 Jan; 25(1):75-84. PubMed ID: 34894233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ketamine for Treatment-Resistant Depression: a New Advocate.
    Pérez-Esparza R
    Rev Invest Clin; 2018; 70(2):65-7. PubMed ID: 29718013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ketamine and the next generation of antidepressants with a rapid onset of action.
    Machado-Vieira R; Salvadore G; Diazgranados N; Zarate CA
    Pharmacol Ther; 2009 Aug; 123(2):143-50. PubMed ID: 19397926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid-onset antidepressant action of ketamine: potential revolution in understanding and future pharmacologic treatment of depression.
    Drewniany E; Han J; Hancock C; Jones RL; Lim J; Nemat Gorgani N; Sperry JK; Yu HJ; Raffa RB
    J Clin Pharm Ther; 2015 Apr; 40(2):125-30. PubMed ID: 25545040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An update on ketamine and its two enantiomers as rapid-acting antidepressants.
    Zhang K; Hashimoto K
    Expert Rev Neurother; 2019 Jan; 19(1):83-92. PubMed ID: 30513009
    [No Abstract]   [Full Text] [Related]  

  • 19. Molecular Mechanism and Clinical Relevance of Ketamine as Rapid-Acting Antidepressant.
    Pešić V; Petrović J; M Jukić M
    Drug Dev Res; 2016 Nov; 77(7):414-422. PubMed ID: 27546787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond.
    Krystal JH; Sanacora G; Duman RS
    Biol Psychiatry; 2013 Jun; 73(12):1133-41. PubMed ID: 23726151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.